Skip to content

Press Release Details

Haemonetics Appoints Bill Burke CFO

Aug 1, 2016

BRAINTREE, Mass., Aug. 1, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) today announced that William P. Burke will join the Company as Chief Financial Officer, effective August 8, 2016. In this role, he will oversee the Company's treasury, controllership and accounting, investor relations, tax and financial planning and analysis functions.

HAE logo April 2016.

Mr. Burke will join the Company directly from Medtronic, Inc. where he has served as Chief Integration Officer for the integration of Covidien into Medtronic since June 2015, filling the key role of principal operating officer for the integration management office. Previously, he held various Finance positions of increasing responsibility over a 20-year career with Covidien and predecessor companies, including CFO – Europe, Vice President of Corporate Strategy and Portfolio Management, and Vice President of Financial Planning and Analysis.

Christopher Simon, Haemonetics' CEO, stated: "Bill Burke is a valuable addition to our team at an important point in time. He is a thoughtful, pragmatic leader with a strong background in all elements of strategy and finance, deep knowledge of the medical device industry and a proven ability to build strong teams that deliver peak performance amid complex change."

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at

Gerry Gould, VP-Investor Relations
(781) 356-9402                                                                          

Sandra Jesse, Executive VP
(781) 356-9253  

Logo -

To view the original version on PR Newswire, visit:

SOURCE Haemonetics Corporation